Connor, Clark & Lunn Investment Management (CC&L)
INSM icon

Connor, Clark & Lunn Investment Management (CC&L)’s Insmed INSM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.7M Buy
212,676
+166,446
+360% +$20.2M 0.04% 337
2026
Q1 		$7.56M Buy
+46,230
New +$7.11M 0.02% 556
2025
Q4 		– Sell
-51,658
Closed -$7.44M – 1642
2025
Q3 		$7.44M Sell
51,658
-174,484
-77% -$21.4M 0.02% 480
2025
Q2 		$22.8M Buy
226,142
+210,999
+1,393% +$16.1M 0.08% 222
2025
Q1 		$1.16M Buy
+15,143
New +$1.16M 0.01% 902
2024
Q3 		– Sell
-41,908
Closed -$2.81M – 1541
2024
Q2 		$2.81M Sell
41,908
-40,175
-49% -$1.56M 0.01% 566
2024
Q1 		$2.23M Sell
82,083
-189,229
-70% -$5.3M 0.01% 639
2023
Q4 		$8.41M Sell
271,312
-174,792
-39% -$4.53M 0.04% 309
2023
Q3 		$11.3M Sell
446,104
-39,355
-8% -$900K 0.06% 240
2023
Q2 		$10.2M Sell
485,459
-30,915
-6% -$587K 0.05% 252
2023
Q1 		$8.8M Sell
516,374
-9,905
-2% -$192K 0.05% 273
2022
Q4 		$10.5M Buy
526,279
+323,503
+160% +$6.25M 0.06% 224
2022
Q3 		$4.37M Buy
202,776
+154,711
+322% +$3.71M 0.03% 340
2022
Q2 		$948K Buy
48,065
+35,205
+274% +$738K 0.01% 639
2022
Q1 		$302K Buy
+12,860
New +$299K ﹤0.01% 872
2016
Q1 		– Sell
-50,100
Closed -$909K – 868
2015
Q4 		$909K Sell
50,100
-25,700
-34% -$453K 0.01% 459
2015
Q3 		$1.41M Sell
75,800
-13,900
-15% -$347K 0.01% 348
2015
Q2 		$2.19M Sell
89,700
-16,100
-15% -$365K 0.02% 226
2015
Q1 		$2.2M Buy
105,800
+34,500
+48% +$608K 0.02% 220
2014
Q4 		$1.1M Buy
+71,300
New +$1.01M 0.01% 296
2014
Q2 		– Sell
-28,200
Closed -$593K – 585
2014
Q1 		$593K Buy
+28,200
New +$536K ﹤0.01% 457
2013
Q4 		– Sell
-23,000
Closed -$369K – 740
2013
Q3 		$369K Buy
23,000
+8,700
+61% +$111K ﹤0.01% 404
2013
Q2 		$180K Buy
+14,300
New +$146K ﹤0.01% 478

Other funds holding INSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s INSM Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Insmed (INSM) stake by 360% in Q2 2026, buying an estimated $20.2M and bringing the position to 212,676 shares worth $22.7M. The position accounts for 0.04% of the portfolio, ranked #337.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in INSM in Q2 2013 and has held it in 23 quarters since. The position peaked at $22.8M in Q2 2025. 663 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 212,676 shares of Insmed worth $22.7M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 166,446 Insmed shares in Q2 2026, an estimated $20.2M.
  • Insmed made up 0.04% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #337 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Insmed in Q2 2013 and has held it in 23 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Insmed position peaked at $22.8M in Q2 2025.
  • 663 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.